Bridget A. Ross Sells 3,750 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) Stock

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Director Bridget A. Ross sold 3,750 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

LeMaitre Vascular Stock Performance

LMAT traded up $0.19 on Tuesday, hitting $103.74. 81,831 shares of the company were exchanged, compared to its average volume of 124,101. The business’s fifty day moving average is $92.45 and its 200 day moving average is $86.15. LeMaitre Vascular, Inc. has a fifty-two week low of $51.70 and a fifty-two week high of $106.49. The firm has a market capitalization of $2.33 billion, a P/E ratio of 56.69, a price-to-earnings-growth ratio of 2.50 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings results on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business had revenue of $54.82 million for the quarter, compared to analysts’ expectations of $53.50 million. During the same quarter in the prior year, the firm posted $0.33 EPS. The company’s revenue was up 15.6% compared to the same quarter last year. Analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 5th. Shareholders of record on Thursday, November 21st will be issued a dividend of $0.16 per share. The ex-dividend date is Thursday, November 21st. This represents a $0.64 annualized dividend and a yield of 0.62%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 34.97%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LMAT. Barrington Research raised their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday, November 1st. Lake Street Capital began coverage on LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 target price for the company. Cantor Fitzgerald assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price objective on the stock. JMP Securities lifted their target price on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 20th. Finally, Oppenheimer reiterated an “outperform” rating and set a $93.00 price target (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $94.57.

Institutional Trading of LeMaitre Vascular

Several institutional investors and hedge funds have recently modified their holdings of the business. NBC Securities Inc. raised its position in shares of LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after purchasing an additional 183 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of LeMaitre Vascular by 57.0% in the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock worth $45,000 after acquiring an additional 199 shares during the last quarter. West Oak Capital LLC acquired a new position in shares of LeMaitre Vascular in the second quarter worth $58,000. USA Financial Formulas purchased a new stake in shares of LeMaitre Vascular in the third quarter valued at $60,000. Finally, nVerses Capital LLC boosted its stake in shares of LeMaitre Vascular by 33.3% during the second quarter. nVerses Capital LLC now owns 800 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 200 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.